ASX ANNOUNCEMENT
12 June 2024

Biome expects to exceed FY24 forecast and report second consecutive positive cashflow and EBITDA quarter

Trading Update

- Biome expects to exceed its upgraded revenue forecast of $12.5m for FY24
- Biome expects to report a second consecutive quarter of positive underlying operating cashflow and EBITDA
- Biome Cholesterol™ Probiotic set for Q1 FY25 launch

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to share a trading update for Q4 FY24.

The June quarter is traditionally the strongest of the financial year for Biome and the company reports that the strong growth in FY24 has continued in Q4 with record sales revenue for April and May.

As a result, Biome expects to exceed its market forecast of $12.5m. The original forecast of $11.5m (ref: ASX announcement dated 5 October 2023) was upgraded to $12.5m and announced to the market on 8 January 2024.

Following the company's first positive underlying cashflow and EBITDA positive quarter in Q3 FY24, Biome expects to report a second consecutive quarter of positive underlying operating cashflow and EBITDA for Q4 FY24. Biome looks forward to providing further details in the upcoming 4C Quarterly Activities Report for Q4 FY24.

Biome is delighted to share that its cholesterol-lowering probiotic is scheduled for launch in Q1 FY25. Biome Cholesterol™ Probiotic will help support healthy cholesterol levels with clinical trial results showing a 14% reduction in cholesterol levels in a 12-week period (ref: ASX announcement dated 21 December 2023).

Cardiovascular diseases are the leading cause of death globally and Biome Cholesterol™ Probiotic will contribute to Biome's core mission of improving health outcomes for patients.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk commented:

"I am pleased to share that Biome is delivering another exceptional quarter of sales revenue growth in Q4 FY24, bolstered by strong sell-through numbers in pharmacy and practitioner channels. With the launch of Biome Cholesterol in Q1 FY25, we feel confident of a strong start to FY25 in our key domestic and international markets. We look forward to sharing further financial updates at the conclusion of FY24. "

-ENDS-

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Jo Power

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance. The historic financial information for the September 2021 financial quarter and revenue figures for October and November 2021 have not been audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.